Lymphoma can be broadly defined as a cancer of mature lymphocytes. Our understanding of the
biology of normal lymphocytes and lymphoma has grown at a tremendous pace and this is now
directly translating into changes in clinical practice. This became evident with the
introduction of one of the first therapeutic monoclonal antibodies into cancer medicine the
CD20-directed antibody rituximab which has led to significant benefit for patients with B-cell
lymphomas. Since then a raft of novel agents has entered clinical practice including targeted
small molecules antibody-drug conjugates bispecific antibodies and chimeric antigen receptor
(CAR) T cells. This new edition of 'Fast Facts: Lymphoma' has been updated to include recent
changes in our understanding of lymphoma biology as well as improvements in diagnostics and
therapeutics.
